Allergan, which is selling its generics business to focus on branded drugs and aesthetics products, aims to acquire or license products that have already shown promise in studies, and leave the riskier discovery process to small biotechs and academic researchers."The best way for us to participate in discovery is investing in a more 'virtual' sense, than actually building and running our own labs," company Chief Executive Brent Saunders said in an interview after Allergan reported second-quarter results on Thursday.
http://www.reuters.com/article/2015/08/06/allergan-medicine-idUSL1N10H3EO20150806
No comments:
Post a Comment